Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Theodoros Foukakis

Showing results (101-110 of 128) with videos related to

Pageof 13
Sort By:
Breast Cancer Research : BCR|January 3, 2024
Identification of a Notch transcriptomic signature for breast cancerEike-Benjamin Braune, Felix Geist, Xiaojia Tang, et al.
BMJ Open|December 9, 2023
ProFertil study protocol for the investigation of gonadotropin-releasing hormone agonists (GnRHa) during chemotherapy aiming at fertility protection of young women and teenagers with cancer in Sweden-a phase III randomised double-blinded placebo-controlled studyKenny A Rodriguez-Wallberg, Hanna Pauline Nilsson, Jonas Bergh, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 27, 2022
Breast cancer patient-derived whole-tumor cell culture model for efficient drug profiling and treatment response predictionXinsong Chen, Emmanouil G Sifakis, Stephanie Robertson, et al.
International Journal of Cancer|December 27, 2024
Prognostic and predictive implications of sterile alpha motif and HD domain-containing protein 1 (SAMHD1) expression in breast cancerMaria Kouvaraki, Ioannis Zerdes, Emmanouil G Sifakis, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 29, 2017
Off-tumor targets compromise antiangiogenic drug sensitivity by inducing kidney erythropoietin productionMasaki Nakamura, Yin Zhang, Yunlong Yang, et al.
Breast Cancer Research : BCR|March 12, 2025
Molecular determinants of response to neoadjuvant pembrolizumab plus chemotherapy in patients with high-risk, early-stage, triple-negative breast cancer: exploratory analysis of the open-label, multicohort phase 1b KEYNOTE-173 studyRebecca Dent, Javier Cortés, Yeon Hee Park, et al.
Breast Cancer Research : BCR|November 29, 2025
Pathological response to pembrolizumab-based neoadjuvant therapy in ER-low vs. ER-zero breast cancer: a Swedish population-based cohort studySanna Steen, Emelie Karlsson, Ida Björnheden, et al.
International Journal of Radiation Oncology, Biology, Physics|January 29, 2020
Five-Year Results of the Preoperative Accelerated Partial Breast Irradiation (PAPBI) TrialSophie C J Bosma, Femke Leij, Sandra Vreeswijk, et al.
Breast Cancer Research and Treatment|January 4, 2024
The role of serum thymidine kinase 1 activity in neoadjuvant-treated HER2-positive breast cancer: biomarker analysis from the Swedish phase II randomized PREDIX HER2 trialYajing Zhu, Ioannis Zerdes, Alexios Matikas, et al.
Annals of Surgical Oncology|February 25, 2026
Surgical Outcomes After Neoadjuvant Pembrolizumab Plus Chemotherapy for Triple-Negative Breast Cancer: Results from the Randomized, Placebo-Controlled Phase 3 KEYNOTE-522 StudySherko Kuemmel, Peter A Fasching, Peter Schmid, et al.
Pageof 13

Showing results (101-110 of 128) with videos related to

Sort By:
Pageof 13
Breast Cancer Research : BCR|January 3, 2024
Identification of a Notch transcriptomic signature for breast cancerEike-Benjamin Braune, Felix Geist, Xiaojia Tang, et al.
BMJ Open|December 9, 2023
ProFertil study protocol for the investigation of gonadotropin-releasing hormone agonists (GnRHa) during chemotherapy aiming at fertility protection of young women and teenagers with cancer in Sweden-a phase III randomised double-blinded placebo-controlled studyKenny A Rodriguez-Wallberg, Hanna Pauline Nilsson, Jonas Bergh, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 27, 2022
Breast cancer patient-derived whole-tumor cell culture model for efficient drug profiling and treatment response predictionXinsong Chen, Emmanouil G Sifakis, Stephanie Robertson, et al.
International Journal of Cancer|December 27, 2024
Prognostic and predictive implications of sterile alpha motif and HD domain-containing protein 1 (SAMHD1) expression in breast cancerMaria Kouvaraki, Ioannis Zerdes, Emmanouil G Sifakis, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 29, 2017
Off-tumor targets compromise antiangiogenic drug sensitivity by inducing kidney erythropoietin productionMasaki Nakamura, Yin Zhang, Yunlong Yang, et al.
Breast Cancer Research : BCR|March 12, 2025
Molecular determinants of response to neoadjuvant pembrolizumab plus chemotherapy in patients with high-risk, early-stage, triple-negative breast cancer: exploratory analysis of the open-label, multicohort phase 1b KEYNOTE-173 studyRebecca Dent, Javier Cortés, Yeon Hee Park, et al.
Breast Cancer Research : BCR|November 29, 2025
Pathological response to pembrolizumab-based neoadjuvant therapy in ER-low vs. ER-zero breast cancer: a Swedish population-based cohort studySanna Steen, Emelie Karlsson, Ida Björnheden, et al.
International Journal of Radiation Oncology, Biology, Physics|January 29, 2020
Five-Year Results of the Preoperative Accelerated Partial Breast Irradiation (PAPBI) TrialSophie C J Bosma, Femke Leij, Sandra Vreeswijk, et al.
Breast Cancer Research and Treatment|January 4, 2024
The role of serum thymidine kinase 1 activity in neoadjuvant-treated HER2-positive breast cancer: biomarker analysis from the Swedish phase II randomized PREDIX HER2 trialYajing Zhu, Ioannis Zerdes, Alexios Matikas, et al.
Annals of Surgical Oncology|February 25, 2026
Surgical Outcomes After Neoadjuvant Pembrolizumab Plus Chemotherapy for Triple-Negative Breast Cancer: Results from the Randomized, Placebo-Controlled Phase 3 KEYNOTE-522 StudySherko Kuemmel, Peter A Fasching, Peter Schmid, et al.
Pageof 13